The Cambridge spinout previously raised a $2.5m series A round backed by the university and up to $3.4m in a 2014 funding round backed by Parkwalk Advisors.
Sphere Fluidics, a life sciences spinout from Cambridge University, has raised £5m ($7m) in a funding round backed by the University of Cambridge Enterprise Fund III and investment firm Parkwalk Advisors’ Technology Funds.
The University of Cambridge Enterprise Fund invests alongside Cambridge University’s own funds to provide private investor access to university spinouts.
Sphere Fluidics has created a platform for single cell analysis and characterisation to discover and develop new biopharmaceuticals and cell therapies. The company has successfully commercialised 55 products so far.
Sphere Fluidics has licensed seven patent families from Cambridge University and other institutions. The core technology is now protected by 54 patents and has been developed with £4m of equity and more than £8m of grants.
In 2013, Sphere Fluidics raised £1.6m in a series A round from, among others, Cambridge University. This was followed in 2014 by a funding round of up to £2m.
